PHARMACEUTICAL STATISTICS

Scope & Guideline

Elevating Pharmaceutical Research with Cutting-Edge Statistical Methods

Introduction

Welcome to the PHARMACEUTICAL STATISTICS information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of PHARMACEUTICAL STATISTICS, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN1539-1604
PublisherWILEY
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 2004 to 2024
AbbreviationPHARM STAT / Pharm. Stat.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address111 RIVER ST, HOBOKEN 07030-5774, NJ

Aims and Scopes

The journal 'Pharmaceutical Statistics' is dedicated to the dissemination of innovative statistical methodologies and their applications in the pharmaceutical and clinical research fields. It focuses on enhancing the design, analysis, and interpretation of clinical trials and other biomedical studies through rigorous statistical frameworks.
  1. Innovative Statistical Methodologies:
    The journal emphasizes the development and application of novel statistical techniques tailored for clinical trials, including Bayesian methods, adaptive designs, and machine learning approaches.
  2. Clinical Trial Design and Analysis:
    A core focus is on optimizing clinical trial designs, such as multi-arm and multi-stage trials, to improve efficiency and decision-making in drug development.
  3. Pharmacokinetics and Pharmacodynamics:
    Research often includes the statistical analysis of pharmacokinetic and pharmacodynamic data, addressing how drugs affect the body and vice versa, which is critical in drug development.
  4. Real-World Evidence and Data Integration:
    The journal explores methodologies for integrating real-world data into clinical trial designs, enhancing the relevance and applicability of trial results in broader populations.
  5. Patient-Reported Outcomes and Quality of Life:
    It also covers statistical methods for analyzing patient-reported outcomes, focusing on how treatments impact patients' quality of life and their overall treatment experience.
The journal exhibits a dynamic evolution in its focus areas, with several emerging themes gaining traction in recent years. These trends highlight the journal's responsiveness to contemporary challenges in pharmaceutical research and statistics.
  1. Bayesian Adaptive Designs:
    There is a significant increase in research on Bayesian adaptive trial designs, which offer flexibility in modifying trial parameters based on interim results, thereby enhancing decision-making during clinical trials.
  2. Machine Learning Applications:
    The integration of machine learning techniques into statistical methodologies is on the rise, particularly for predicting treatment outcomes and analyzing complex datasets, reflecting the industry's push towards data-driven approaches.
  3. Real-World Evidence Utilization:
    The use of real-world evidence in clinical trial designs and post-marketing surveillance is becoming more prominent, emphasizing the need to understand how treatments perform in broader, more diverse patient populations.
  4. Patient-Centric Approaches:
    There is a growing emphasis on patient-centered methodologies, particularly in analyzing patient-reported outcomes and incorporating patient preferences into trial designs, which aligns with the broader movement towards personalized medicine.
  5. Hybrid Clinical Trials:
    Research on hybrid clinical trial designs that combine elements of traditional randomized controlled trials with real-world data is emerging, indicating a shift towards more innovative and adaptable research frameworks.

Declining or Waning

While 'Pharmaceutical Statistics' continues to thrive in various areas, certain themes appear to be losing prominence in recent publications. These declining scopes reflect shifts in research focus and methodological preferences within the field.
  1. Traditional Frequentist Approaches:
    There is a noticeable decline in the emphasis on traditional frequentist statistical methods. The growing preference for Bayesian approaches suggests a shift towards more flexible modeling frameworks that can incorporate prior information.
  2. Single-Endpoint Trials:
    Research focused solely on single endpoints in clinical trials is becoming less common, with a trend towards multi-endpoint designs that provide a more comprehensive evaluation of treatment effects.
  3. Basic Statistical Theory:
    Publications that delve deeply into basic statistical theory without direct application to practical problems are waning, as the field increasingly favors applied methodologies and real-world applications.
  4. Conventional Data Handling Techniques:
    The use of conventional data handling methods, such as simple imputation techniques, is decreasing in favor of more advanced approaches that address complexities in missing data and incorporate machine learning techniques.

Similar Journals

Clinical Pharmacology in Drug Development

Bridging research and practice in drug development.
Publisher: WILEYISSN: 2160-7648Frequency: 6 issues/year

Clinical Pharmacology in Drug Development, published by WILEY, is a distinguished journal dedicated to advancing the field of pharmaceutical science and drug development. With a strong commitment to disseminating cutting-edge research, this journal serves as a crucial platform for professionals, researchers, and students aiming to enhance their understanding of pharmacological principles and innovations in medical therapeutics. Since its inception in 2012, the journal has consistently maintained a noteworthy presence in the academic community, currently achieving a Q2 ranking in both Pharmaceutical Science and Medical Pharmacology categories as of 2023. Although the journal operates under a subscription model, it is highly regarded for its rigorous peer-reviewed publications, offering insights into drug efficacy, safety, and regulatory challenges. Positioned at the intersection of clinical practices and pharmaceutical advancements, Clinical Pharmacology in Drug Development plays an essential role in bridging the gap between scientific research and real-world application, ensuring that the latest therapeutic strategies are optimized for patient care.

STATISTICS

Pioneering research that addresses contemporary statistical challenges.
Publisher: TAYLOR & FRANCIS LTDISSN: 0233-1888Frequency: 6 issues/year

STATISTICS is a distinguished journal published by Taylor & Francis Ltd, dedicated to advancing the field of statistical science since its inception in 1985. With a strong focus on both the theoretical and practical aspects of Statistics and Probability, this journal serves as a vital platform for researchers, professionals, and students seeking to disseminate their findings and contribute to critical discussions in the discipline. Although categorized in the Q3 quartile for both Statistics and Probability and Statistics, Probability and Uncertainty, the journal's commitment to quality research is evidenced by its inclusion in relevant Scopus rankings. It holds respectable positions, ranked #132/168 in Decision Sciences and #219/278 in Mathematics. By providing a venue for high-quality research articles and reviews, STATISTICS aims to foster innovation, reinforce methodological advancements, and address contemporary challenges in statistical applications. The journal does not currently offer open access, but it is widely distributed, ensuring that significant research reaches the communities that need it most. Researchers are encouraged to submit their work to this essential resource that continues to shape the landscape of statistical inquiry.

JIRSS-Journal of the Iranian Statistical Society

Connecting Researchers to the Pulse of Statistical Innovation.
Publisher: IRANIAN STATISTICAL SOCISSN: 1726-4057Frequency: 2 issues/year

JIRSS - Journal of the Iranian Statistical Society is a prominent academic journal dedicated to the field of statistics and probability, published by the esteemed Iranian Statistical Society. With its ISSN number 1726-4057 and E-ISSN 2538-189X, this journal serves as a vital platform for disseminating cutting-edge research and advancements in statistical methodology and its applications. Established in 2011, JIRSS has consistently contributed to the academic community, achieving a 2023 Scopus rank of #180 out of 278 in its category, placing it within the 35th percentile in the dynamic domain of Mathematics: Statistics and Probability. As an Open Access publication, it enhances accessibility for researchers, professionals, and students, facilitating a wider engagement with innovative statistical techniques and theories. The journal aims to foster collaboration and knowledge exchange among statisticians, ultimately enriching the field and its impact on various scientific disciplines.

Journal of Biopharmaceutical Statistics

Fostering scientific breakthroughs with precision and rigor.
Publisher: TAYLOR & FRANCIS INCISSN: 1054-3406Frequency: 6 issues/year

Journal of Biopharmaceutical Statistics, published by Taylor & Francis Inc, is a premier scholarly journal that has been contributing to the fields of biostatistics and pharmacology since its inception in 1991. With an impressive track record spanning over three decades, it holds a significant place in the academic landscape, particularly evidenced by its Q2 quartile rankings in Pharmacology, Pharmacology (Medical), and Statistics and Probability as of 2023. The journal serves as a vital platform for researchers, professionals, and students, disseminating critical statistical methodologies and innovative analyses that enhance drug development and biopharmaceutical research. Although not open access, it provides invaluable insights through meticulously peer-reviewed articles that tackle pressing issues in pharmacometric modeling, clinical trial design, and statistical theory. As the biopharmaceutical industry evolves, Journal of Biopharmaceutical Statistics remains pivotal in fostering scientific discovery and excellence.

International Journal of Biostatistics

Exploring Innovations in Biostatistical Applications.
Publisher: WALTER DE GRUYTER GMBHISSN: 2194-573XFrequency: 2 issues/year

The International Journal of Biostatistics, published by Walter de Gruyter GmbH, stands as a critical platform for advancements in the fields of biostatistics and applied statistics in medicine. With an ISSN of 2194-573X and an E-ISSN of 1557-4679, this journal has gained recognition for its rigorous peer-reviewed articles that bridge theoretical statistics and its practical applications in health sciences, maintaining a commendable Q2 quartile ranking in both Medicine and Statistics categories as of 2023. Hosted in Germany, the journal's pivotal role lies in disseminating innovative research findings that guide public health decisions and inform healthcare policy, thus appealing to a diverse readership including researchers, healthcare professionals, and students. Although the journal operates under a subscription model, it remains committed to providing valuable insights into the statistical methods that support evidence-based medicine and improve health outcomes globally. For those engaged in the evolving landscape of biostatistics, the International Journal of Biostatistics serves as an indispensable resource through its comprehensive coverage from 2005 to 2024.

Clinical Trials

Advancing clinical research for a healthier tomorrow.
Publisher: SAGE PUBLICATIONS LTDISSN: 1740-7745Frequency: 6 issues/year

Clinical Trials, published by SAGE Publications Ltd, is a prestigious journal that serves as a vital resource for researchers, professionals, and students in the fields of medicine and pharmacology. Operating since 2004 and converging through 2024, this journal boasts an impressive standing in the academic community, achieving a Q1 categorization in both Medicine (miscellaneous) and Pharmacology as of 2023. The journal's Scopus rankings reflect its influential contributions, with a rank of #128 out of 636 in General Medicine and a 79th percentile placement, alongside a rank of #172 out of 313 in Pharmacology, indicating its significant role in advancing clinical research. Based in the United Kingdom, Clinical Trials focuses on disseminating high-quality studies that enhance the understanding of clinical processes and therapeutic methodologies. Although it does not currently offer Open Access, the journal provides a platform for traditional publication, ensuring the dissemination of critical knowledge in the healthcare domain.

Contemporary Clinical Trials

Pioneering Excellence in Clinical Research
Publisher: ELSEVIER SCIENCE INCISSN: 1551-7144Frequency: 6 issues/year

Contemporary Clinical Trials, published by Elsevier Science Inc, stands at the forefront of clinical research, providing a dedicated platform for the dissemination of innovative studies and methodologies in medicine and pharmacology. With an impressive impact factor reflecting its consistent contributions to the field, this journal is categorized in the Q1 quartile for both Medicine (miscellaneous) and Pharmacology (medical) as of 2023. The journal's scope encompasses a broad range of topics pertinent to clinical trial design, execution, and analysis, aiming to enhance the effectiveness and safety of therapeutic interventions. Operating under an Open Access model, it ensures that the latest research is accessible to a global audience, fostering collaboration and discussion among researchers, professionals, and students alike. In publishing high-quality articles since its inception in 2005, Contemporary Clinical Trials continues to shape the future of clinical research with its commitment to excellence and innovation.

Contemporary Clinical Trials Communications

Advancing Clinical Research for a Healthier Tomorrow
Publisher: ELSEVIER INCISSN: Frequency:

Contemporary Clinical Trials Communications, published by ELSEVIER INC, serves as a pivotal resource in the evolving fields of medicine and pharmacology, especially with its commitment to open access since 2015. With the E-ISSN 2451-8654, this journal is dedicated to disseminating high-quality research that examines contemporary clinical trial methodologies and their applications in improving healthcare outcomes. Situated in the United States, its impressive ranking, with a Q2 status in both Medicine (miscellaneous) and Pharmacology for 2023, highlights its significance and impact within the scientific community. Ranking #199 out of 636 in General Medicine and #217 out of 313 in Pharmacology on the Scopus scale, the journal aims to foster innovative discussions and developments among researchers, professionals, and students, making it an essential tool for those seeking to stay at the forefront of clinical research and trials.

Trials

Driving collaboration in the pursuit of medical breakthroughs.
Publisher: BMCISSN: Frequency: 1 issue/year

Trials, published by BMC, is a leading open access journal that has been pioneering advancements in the field of medicine and pharmacology since its inception in 2006. With an impressive E-ISSN of 1745-6215, the journal is based in the United Kingdom and operates from its address at CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND. Trials is recognized for its impactful contributions to the research community, achieving a Q2 ranking in both the Medicine (miscellaneous) and Pharmacology (medical) categories according to the 2023 category quartiles. This esteemed journal aims to provide a platform for presenting cutting-edge clinical trials and methodological advances, effectively fostering collaboration and innovation among researchers, professionals, and students. The journal's accessibility, supported by its open access model, enhances the visibility and dissemination of vital research findings, ensuring that every contribution reaches a broad audience. As of 2024, Trials continues to be a crucial resource for anyone passionate about exploring new frontiers in medical research.

BIOMETRICAL JOURNAL

Empowering researchers with high-impact statistical insights.
Publisher: WILEYISSN: 0323-3847Frequency: 6 issues/year

BIOMETRICAL JOURNAL is a prestigious academic publication dedicated to advancing the fields of Medicine and Statistics. Published by WILEY since its inception in 1977, this journal plays a critical role in disseminating cutting-edge research and methodologies that bridge the gap between statistical theory and real-world medical applications. With an impressive Q1 ranking in both Medicine (miscellaneous) and Statistics, Probability and Uncertainty, it is recognized for its high-impact contributions to the scientific community. The journal actively encourages submissions that utilize innovative statistical techniques to address complex biomedical issues, making it an essential resource for researchers, professionals, and students aiming to enhance their understanding of quantitative approaches in health and medicine. Although the journal is not open access, its rigorous peer-review process guarantees the quality and relevance of published works, further establishing its significance in the academic landscape.